Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Lactoferricin
Overview
Lactoferricin is a cationic antimicrobial peptide derived from pepsin-mediated cleavage of lactoferrin, an iron-binding glycoprotein found in milk and mucosal secretions. The most studied variant, bovine lactoferricin B, is a 25-amino acid peptide that disrupts microbial membranes and chelates iron, contributing to its broad-spectrum antimicrobial activity.
Mechanism of Action
Lactoferricin exhibits antibacterial, antifungal, antiviral, and antiparasitic properties, along with immunomodulatory effects. Its natural origin and multifunctional activity have generated interest in food preservation, oral health, and topical antimicrobial applications.
Research Summary & Key Findings
In vitro studies and animal models have demonstrated antimicrobial efficacy against a range of pathogens, including antibiotic-resistant strains. Small human trials have explored lactoferricin or lactoferrin-derived peptides in oral health applications such as periodontitis and dental caries prevention, with mixed results. Large-scale clinical development has been limited, and most applications remain in preclinical or early-phase investigation.
Clinical Status
Lactoferricin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Lactoferricin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Lactoferricin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Lactoferricin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Antimicrobial
Enfuvirtide (Fuzeon)
FDA ApprovedA 36-amino acid synthetic peptide that inhibits HIV-1 entry into CD4+ T-cells by blocking the gp41-mediated membrane fus...
View detailsMagainin 2
Research PhaseMagainin 2 is a 23-amino acid antimicrobial peptide originally isolated from the skin of the African clawed frog Xenopus...
View detailsPexiganan (MSI-78)
In Clinical TrialsPexiganan is a 22-amino acid synthetic analog of magainin 2 designed to enhance antimicrobial potency and proteolytic st...
View detailsOmiganan
In Clinical TrialsOmiganan is a synthetic 12-amino acid cationic antimicrobial peptide derived from indolicidin, a naturally occurring pep...
View detailsNo lawful pathway today
Lactoferricin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.